Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25,964 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts.
Yi JH, Jeong SH, Kim SJ, Yoon DH, Kang HJ, Koh Y, Kim JS, Lee WS, Yang DH, Do YR, Kim MK, Yoo KH, Choi YS, Yun WJ, Park Y, Jo JC, Eom HS, Kwak JY, Shin HJ, Park BB, Yi SY, Kwon JH, Oh SY, Kim HJ, Sohn BS, Won JH, Hong DS, Lee HS, Lee GW, Suh C, Kim WS. Yi JH, et al. Among authors: park bb, park y. Cancer Res Treat. 2023 Jan;55(1):325-333. doi: 10.4143/crt.2022.008. Epub 2022 Apr 22. Cancer Res Treat. 2023. PMID: 35468269 Free PMC article.
Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis.
Hong J, Kim SJ, Ahn JS, Song MK, Kim YR, Lee HS, Yhim HY, Yoon DH, Kim MK, Oh SY, Park Y, Mun YC, Do YR, Ryoo HM, Lee JJ, Lee JH, Kim WS, Suh C. Hong J, et al. Among authors: park y. Cancer Res Treat. 2015 Apr;47(2):173-81. doi: 10.4143/crt.2014.055. Epub 2014 Oct 28. Cancer Res Treat. 2015. PMID: 25544581 Free PMC article.
Body Cavity-Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma.
Shin J, Ko YH, Oh SY, Yoon DH, Lee JO, Kim JS, Park Y, Shin HJ, Kim SJ, Won JH, Yoon SS, Kim WS, Koh Y; Consortium for Improving Survival of Lymphoma investigators. Shin J, et al. Among authors: park y. Cancer Res Treat. 2019 Oct;51(4):1302-1312. doi: 10.4143/crt.2018.555. Epub 2019 Feb 14. Cancer Res Treat. 2019. PMID: 30764603 Free PMC article.
Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study.
Jeong SH, Kim SJ, Yoon DH, Park Y, Kang HJ, Koh Y, Lee GW, Lee WS, Yang DH, Do YR, Kim MK, Yoo KH, Choi YS, Yun HJ, Yi JH, Jo JC, Eom HS, Kwak JY, Shin HJ, Park BB, Hyun SY, Yi SY, Kwon JH, Oh SY, Kim HJ, Sohn BS, Won JH, Kim SH, Lee HS, Suh C, Kim WS. Jeong SH, et al. Among authors: park bb, park y. Cancer Res Treat. 2022 Oct;54(4):1268-1277. doi: 10.4143/crt.2021.1168. Epub 2021 Dec 30. Cancer Res Treat. 2022. PMID: 34990525 Free PMC article.
Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin's Lymphoma: A Multicenter Randomized Phase II Study bythe Consortium for Improving Survival of Lymphoma (CISL).
Kim KH, Lee JH, Lee M, Kim HG, Do YR, Park Y, Oh SY, Shin HJ, Kim WS, Park SK, Kong JH, Park MR, Yang DH, Kwak JY, Kang HJ, Mun YC, Won JH. Kim KH, et al. Among authors: park y, park sk, park mr. Cancer Res Treat. 2023 Jan;55(1):304-313. doi: 10.4143/crt.2022.004. Epub 2022 Mar 30. Cancer Res Treat. 2023. PMID: 35381164 Free PMC article. Clinical Trial.
Glucose transporter-1 expression in squamous cell carcinoma of the tongue.
Choi YS, Kim SJ, Kim DS, Park SJ, Park Y, Shin HJ, Jung KY, Baek SK, Shin BK, Choi JW, Kim BS, Shin SW, Kim YH, Kim JS. Choi YS, et al. Among authors: park y, park sj. Cancer Res Treat. 2007 Sep;39(3):109-15. doi: 10.4143/crt.2007.39.3.109. Epub 2007 Sep 30. Cancer Res Treat. 2007. PMID: 19746220 Free PMC article.
Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity.
Kim SJ, Kim K, Park Y, Kim BS, Huh J, Ko YH, Park K, Suh C, Kim WS. Kim SJ, et al. Among authors: park y, park k. Invest New Drugs. 2012 Feb;30(1):368-75. doi: 10.1007/s10637-010-9523-2. Epub 2010 Aug 24. Invest New Drugs. 2012. PMID: 20734108 Clinical Trial.
25,964 results
You have reached the last available page of results. Please see the User Guide for more information.